|
Produced by French drug maker Sanofi-Aventis, Lantus® is a sterile solution of insulin glargine, made for injection in patients with diabetes. Lantus and the FDA Lantus® was the first FDA approved long-acting (basal) recombinant human insulin analog. Based on recent studies, the FDA issued a MedWatch Safety Alert acknowledging that those on Lantus® could be facing an increased risk of developing cancer. From the Food and Drug Administration MedWatch Safety Alert: “FDA notified healthcare professionals and patients that it is aware of four recently-published observational studies that looked at the use of Lantus (insulin glargine) and possible risk for cancer in patients with diabetes. Three of the four studies suggest an increased risk for cancer associated with use of Lantus.” Lantus® Possible Link with Cancer The Diabetes Journal Diabetologia published the results of four large studies on Lantus in June of 2009, with a patient base from Scotland, Sweden, UK and Germany. The German subjects were from an insurance database of approximately 127,000 insulin-treated patients. The results? A possible link was suggested between Lantus and an increased risk of developing cancer. Diabetologia Press Release: “Compared with people using similar doses of human insulin, out of every 100 people who used Lantus insulin over an average of about one-and-a-half years, one additional person was diagnosed with cancer.” The study also found that the risk of cancer was dose-dependent; those taking higher doses of Lantus seemed to be at greater risk for developing cancer. After looking at these results, the European Association for the Study of Diabetes (EASD) made "an urgent call for more research into a possible link between use of insulin glargine (an insulin analogue, brand name Lantus) and increased risk of cancer, following evidence from studies in Germany, Sweden and Scotland.” Diabetes and Insulin Worldwide, there is an estimated 200 million people with diabetes; about 10% develop diabetes in early life. People with type 1 diabetes are absolutely dependent on insulin treatment in order to maintain health. Type 2 diabetes, associated with excess weight, forms the remaining 90%, developing later in life. People with type 2 diabetes can supply some of their own insulin in the early stages of the disease, but later in life many patients with type 2 diabetes lose the ability to produce their own insulin, and then rely on insulin injections to maintain health. Never discontinue any medication without the consent of your physician. The Mulligan Law Firm provides legal information and resources for injured individuals and their families. A national law firm located in Dallas, Texas, and Newport Beach, California. The Mulligan Law Firm has successfully resolved over $600,000,000 in claims for its clients. Formed in 1995, it has been helping people for almost 15 years, with the strength and experience to represent plaintiffs in all 50 states. The Mulligan Law Firm is currently investigating injury claims involving Lantus. If you or a loved one has been diagnosed with cancer after taking Lantus, it is important that you consult with a legal professional immediately. For a free evaluation of your potential claim, call 1-888-446-8087, or fill out an intake form on this website by clicking on "Can We Help You?" on the upper right hand corner of the home page. You may be entitled to compensation for your injuries. We take all cases on a contingency-fee basis, which means you do not pay for our services unless you receive an award or compensation. Do not delay, as your rights and compensation may be lost forever if you wait.
|
